The Phase 1 study, a non-randomised, open-label, multicentre trial, is evaluating IKS014 in patients with locally advanced or metastatic solid tumours expressing HER2
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
The supplements are made using only vegetarian-sourced ingredients
The guidelines also support reusing tenofovir and abacavir in later regimens for improved outcomes, cost savings, and programmatic efficiency
The partnership builds on a prior collaboration between Nimbus and Lilly targeting AMPK in cardiometabolic diseases
The approval is backed by data showing deep, durable responses and manageable tolerability
Tiger Shroff fronts ‘Fit Raho, Hit Raho’ campaign
The trial aims to measure AF burden—the percentage of time patients spend in arrhythmia—as its primary efficacy endpoint
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
Blood tests measuring biomarkers such as p-tau217 are emerging as accurate, accessible alternatives
Subscribe To Our Newsletter & Stay Updated
